You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Last Updated: December 3, 2023

Brilliant blue g - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for brilliant blue g and what is the scope of patent protection?

Brilliant blue g is the generic ingredient in one branded drug marketed by Dutch Ophthalmic and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for brilliant blue g
US Patents:0
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 90
Clinical Trials: 6
Patent Applications: 2,398
What excipients (inactive ingredients) are in brilliant blue g?brilliant blue g excipients list
DailyMed Link:brilliant blue g at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for brilliant blue g
Generic Entry Date for brilliant blue g*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for brilliant blue g

Identify potential brand extensions & 505(b)(2) entrants

Xinhua Hospital, Shanghai Jiao Tong University School of MedicineN/A
Anthera PharmaceuticalsPhase 3
Asociación para Evitar la Ceguera en MéxicoPhase 3

See all brilliant blue g clinical trials

Pharmacology for brilliant blue g
Drug ClassDisclosing Agent
Mechanism of ActionDyes

US Patents and Regulatory Information for brilliant blue g

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dutch Ophthalmic TISSUEBLUE brilliant blue g SOLUTION;OPHTHALMIC 209569-001 Dec 20, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Dutch Ophthalmic TISSUEBLUE brilliant blue g SOLUTION;OPHTHALMIC 209569-001 Dec 20, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.